FREDERICK M HECHT, MD
Osteopathic Medicine in San Francisco, CA
License number
California G71793
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
995 Ward 84 BLDG 80, San Francisco, CA 94110
Phone
(415) 476-4082
(415) 476-6953 (Fax)
(415) 206-3103
(415) 206-3872 (Fax)
(415) 476-6953 (Fax)
(415) 206-3103
(415) 206-3872 (Fax)
Personal information
See more information about FREDERICK M HECHT at radaris.comName
Address
Phone
196 Patricia Dr, Atherton, CA 94027
621 S Virgil Ave SUITE 450, Los Angeles, CA 90005
1333 Lawrence Expy #212, Santa Clara, CA 95051
2810 Fulton St, Berkeley, CA 94705
1605 Parkmoor Ave #205, San Jose, CA 95128
Professional information
See more information about FREDERICK M HECHT at trustoria.com
Dr. Frederick M Hecht, San Francisco CA - MD (Doctor of Medicine)
Dr. Frederick M Hecht, San Francisco CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
1001 Potrero Ave SUITE 80, San Francisco 94110
995 Potrero Ave SUITE 80, San Francisco 94110
(415) 476-4082 (Phone), (415) 476-6953 (Fax)
MEDICINE RM 5H-22
1001 Potrero Ave, San Francisco 94110
(415) 206-8361 (Phone), (415) 206-3872 (Fax)
995 Potrero Ave SUITE 80, San Francisco 94110
(415) 476-4082 (Phone), (415) 476-6953 (Fax)
MEDICINE RM 5H-22
1001 Potrero Ave, San Francisco 94110
(415) 206-8361 (Phone), (415) 206-3872 (Fax)
Certifications:
Internal Medicine, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1001 Potrero Ave SUITE 80, San Francisco 94110
995 Potrero Ave SUITE 80, San Francisco 94110
MEDICINE RM 5H-22
1001 Potrero Ave, San Francisco 94110
UCSF Medical Center at Mount Zion
1600 Divisadero St, San Francisco 94115
995 Potrero Ave SUITE 80, San Francisco 94110
MEDICINE RM 5H-22
1001 Potrero Ave, San Francisco 94110
UCSF Medical Center at Mount Zion
1600 Divisadero St, San Francisco 94115
Education:
Medical School
Suny Downstate Medical Center
Graduated: 1986
Montefiore Medical Center-Moses Division
University Of California-San Francisco
Suny Downstate Medical Center
Graduated: 1986
Montefiore Medical Center-Moses Division
University Of California-San Francisco
Frederick M Hecht, San Francisco CA
Frederick M Hecht, San Francisco CA
Specialties:
Internist
Address:
995 Potrero Ave, San Francisco, CA 94110
Education:
State University of New York Downstate Medical Center, College of Medicine - Doctor of Medicine
UCSF Medical Center - Fellowship - Gastroenterology (Internal Medicine)
UCSF Medical Center - Fellowship - Gastroenterology (Internal Medicine)
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Frederick Malcolm Hecht, San Francisco CA
Frederick Malcolm Hecht, San Francisco CA
Specialties:
Internal Medicine, Pediatrics
Work:
San Francisco General Hospital Medical Center
995 Potrero Ave, San Francisco, CA 94110
995 Potrero Ave, San Francisco, CA 94110
Education:
State University of New York Downstate (1986)
Human Endogenous Retrovirus Polypeptide Compositions And Methods Of Use Thereof
Human Endogenous Retrovirus Polypeptide Compositions And Methods Of Use Thereof
US Patent:
2008017, Jul 17, 2008
Filed:
Jul 19, 2007
Appl. No.:
11/880126
Inventors:
Douglas Nixon - San Francisco CA, US
Keith Garrison - San Francisco CA, US
Duncan Meiklejohn - San Francisco CA, US
Mario Ostrowski - Toronto, CA
R. Bradley Jones - Bronx NY, US
Ashish Agrawal - San Francisco CA, US
Jack Lenz - Bronx NY, US
Frederick M. Hecht - San Francisco CA, US
Keith Garrison - San Francisco CA, US
Duncan Meiklejohn - San Francisco CA, US
Mario Ostrowski - Toronto, CA
R. Bradley Jones - Bronx NY, US
Ashish Agrawal - San Francisco CA, US
Jack Lenz - Bronx NY, US
Frederick M. Hecht - San Francisco CA, US
International Classification:
A61K 39/21, A61K 31/70, C07K 16/00, C12N 5/00
US Classification:
4241871, 514 44, 530403, 435375
Abstract:
The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide.
Human Endogenous Retrovirus Polypeptide Compositions And Methods Of Use Thereof
Human Endogenous Retrovirus Polypeptide Compositions And Methods Of Use Thereof
US Patent:
2013032, Dec 5, 2013
Filed:
May 10, 2013
Appl. No.:
13/891970
Inventors:
- Toronto, CA
R. Bradley Jones - Toronto, CA
Ashish Agrawal - San Francisco CA, US
Jack Lenz - Bronx NY, US
Frederick M. Hecht - San Francisco CA, US
R. Bradley Jones - Toronto, CA
Ashish Agrawal - San Francisco CA, US
Jack Lenz - Bronx NY, US
Frederick M. Hecht - San Francisco CA, US
Assignee:
The J. David Gladstone Institutes - San Francisco CA
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
The Regents of the University of California - Oakland CA
The Governing Counicl of University of Toronto - Toronto
Albert Einstein College of Medicine of Yeshiva University - Bronx NY
The Regents of the University of California - Oakland CA
The Governing Counicl of University of Toronto - Toronto
International Classification:
A61K 39/21
US Classification:
4242071
Abstract:
The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide.
Long Interspersed Nuclear Element Polypeptide Compositions And Methods Of Use Thereof
Long Interspersed Nuclear Element Polypeptide Compositions And Methods Of Use Thereof
US Patent:
2011004, Feb 24, 2011
Filed:
Sep 19, 2008
Appl. No.:
12/677278
Inventors:
Douglas F. Nixon - San Francisco CA, US
Keith Garrison - Alameda CA, US
Duncan Meiklejohn - West Lebanon NH, US
Mario Ostrowski - Toronto, CA
R. Bradley Jones - Toronto, CA
Ashish Agrawal - Fremont CA, US
Frederick M. Hecht - San Francisco CA, US
Keith Garrison - Alameda CA, US
Duncan Meiklejohn - West Lebanon NH, US
Mario Ostrowski - Toronto, CA
R. Bradley Jones - Toronto, CA
Ashish Agrawal - Fremont CA, US
Frederick M. Hecht - San Francisco CA, US
Assignee:
THE J. DAVID GLADSTONE INSTITUTES - San Francisco CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 38/08, C07K 7/06, C07H 21/04, C07K 7/08, A61P 31/18, C12N 15/63, A61K 31/7088, A61K 38/10, C12Q 1/02, A61P 35/00, A61P 31/12
US Classification:
514 37, 514 216, 530328, 536 231, 530327, 4353201, 514 44 R, 514 38, 514 215, 435 29
Abstract:
The present invention provides LINE polypeptides; and compositions, including immunogenic compositions, comprising a subject LINE polypeptide. The present invention provides a recombinant nucleic acid comprising a nucleotide sequence encoding a subject LINE polypeptide. A subject composition is useful for stimulating a T-cell immune response to a LINE peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers that are associated with tissues in which LINE polypeptides are aberrantly expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a LINE polypeptide.